Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is presented as a cabozantinib medicine in 20 mg and 80 mg strengths. Cabozantinib is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It works by blocking selected proteins involved in cancer-cell signaling, tumor growth, and the development of blood vessels that supply tumors.

Cabozantinib is used in specific cancer-treatment settings. Its clinical applications depend on the formulation, cancer type, previous treatment, and applicable regulatory approval. Treatment must be prescribed and supervised by a qualified oncology professional.

What Is Cabozantinib?

Cabozantinib is a multi-target receptor tyrosine kinase inhibitor. Receptor tyrosine kinases are proteins that help regulate important cellular activities, including growth, survival, movement, and communication between cells.

Some cancers use abnormal signaling through these proteins to support their development and progression. Cabozantinib blocks several of these signaling pathways, potentially interfering with processes that help tumors grow and spread.

Its important molecular targets include:

  • MET: Involved in cell growth, survival, movement, and invasion.
  • VEGFR1, VEGFR2, and VEGFR3: Involved in signaling associated with blood-vessel formation.
  • AXL: Associated with cell survival, migration, invasion, and cancer progression.
  • RET: A receptor tyrosine kinase involved in cellular signaling.
  • KIT: A protein involved in cell growth and development.

Cabozantinib acts on multiple targets rather than a single cancer-related protein.

Clinical Uses of Cabozantinib

The approved indications for cabozantinib differ according to the formulation and country. The following are established treatment settings for specific cabozantinib products and should not automatically be interpreted as confirmed Caboxen indications.

1. Renal Cell Carcinoma

Renal cell carcinoma (RCC) is the most common type of kidney cancer. It develops when abnormal cells in the kidney grow uncontrollably and form a tumor.

Cabozantinib tablets are used in specified settings for advanced renal cell carcinoma. Depending on the applicable approval and treatment circumstances, cabozantinib may be prescribed alone or in combination with another anticancer medicine.

Treatment decisions may consider:

  • The stage and progression of the cancer.
  • Previous cancer treatments.
  • The patient’s general health.
  • Kidney and liver function.
  • Other medical conditions.
  • Potential benefits and treatment-related risks.

The treating oncologist determines whether cabozantinib is appropriate for an individual patient.

2. Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a primary cancer that begins in liver cells. It is commonly associated with underlying liver disease.

Cabozantinib tablets have an established role in certain patients with hepatocellular carcinoma who have previously received specified treatment.

Important considerations include liver function, previous treatment, disease progression, and the patient’s overall medical condition.

Because cabozantinib can cause serious adverse reactions, patients receiving treatment require appropriate clinical monitoring.

3. Differentiated Thyroid Cancer

Differentiated thyroid cancer develops from thyroid cells that retain certain characteristics of normal thyroid tissue.

Certain patients with differentiated thyroid cancer may be eligible for cabozantinib tablets when their disease meets specific treatment criteria.

These criteria can include disease progression following previous systemic treatment and radioiodine-refractory or radioiodine-ineligible status, depending on the applicable regulatory approval.

Cabozantinib is not suitable for every patient with thyroid cancer. Treatment decisions require specialist assessment.

4. Neuroendocrine Tumors

Neuroendocrine tumors develop from cells that have characteristics of both nerve cells and hormone-producing cells. They can occur in different organs, including the pancreas and gastrointestinal tract.

Cabozantinib tablets have an established treatment role in certain previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in jurisdictions where the indication is approved.

Treatment eligibility depends on tumor characteristics, disease progression, previous therapy, and individual clinical circumstances.

5. Medullary Thyroid Cancer

Medullary thyroid cancer develops from the parafollicular C cells of the thyroid gland, which produce calcitonin.

The cabozantinib capsule formulation has a separate established indication for progressive metastatic medullary thyroid cancer under its applicable regulatory approval.

This indication is formulation-specific and should not automatically be attributed to all cabozantinib products.

How Does Cabozantinib Work?

Cabozantinib blocks several receptor tyrosine kinases involved in cancer-related signaling.

Tumors may depend on signals that encourage abnormal cell growth, survival, movement, and the development of new blood vessels. These processes can support tumor expansion and progression.

Cabozantinib inhibits selected signaling pathways involved in these activities.

Inhibition of Tumor Blood-Vessel Formation

VEGF receptors participate in angiogenesis, the process through which new blood vessels develop.

Tumors can stimulate blood-vessel formation to obtain oxygen and nutrients. Cabozantinib inhibits VEGF receptor signaling, interfering with pathways involved in tumor-associated angiogenesis.

Inhibition of MET Signaling

MET is involved in cellular growth, survival, and movement. Abnormal MET activity may contribute to tumor progression.

Cabozantinib inhibits MET signaling and may interfere with processes associated with cancer-cell survival and invasion.

Inhibition of AXL Signaling

AXL is associated with cell survival, migration, and invasion. It may also contribute to cancer progression and treatment resistance in certain biological settings.

Cabozantinib’s activity against AXL forms part of its multi-target pharmacological action.

The overall clinical response varies among patients and depends on the cancer type, tumor biology, treatment history, and individual health factors.

Dosage and Administration Considerations

Cabozantinib is an oral medicine, but the appropriate dosage depends on the exact formulation and treatment indication.

The reference tablet and capsule formulations have different recommended doses and administration instructions.

For example:

  • The reference tablet formulation is generally taken on an empty stomach, at least one hour before or at least two hours after food.
  • The reference capsule formulation has a different fasting requirement.

These instructions must not be interchanged.

The stated Caboxen strengths are 20 mg and 80 mg, but the exact dosage form must be confirmed before applying capsule-specific or tablet-specific instructions.

The prescribed dose may be modified by the treating healthcare professional if serious or persistent adverse reactions occur.

Patients should never change their dose independently.

Important Clinical Safety Information

Cabozantinib can cause serious and potentially life-threatening adverse reactions. Appropriate medical supervision is necessary throughout treatment.

Important safety concerns include:

High Blood Pressure

Cabozantinib can cause hypertension. Blood pressure should be assessed before and during treatment. Severe or uncontrolled hypertension may require medical intervention or treatment modification.

Bleeding

Serious hemorrhage can occur. Patients should report unusual bleeding, blood in the stool or urine, coughing up blood, or other concerning symptoms.

Blood Clots

Cabozantinib may increase the risk of thromboembolic complications. Symptoms such as chest pain, sudden breathing difficulty, or swelling and pain in a limb require prompt medical assessment.

Gastrointestinal Perforation and Fistula

Gastrointestinal perforation and fistula formation are serious possible complications. Severe abdominal pain, persistent vomiting, fever, or unusual gastrointestinal symptoms should be assessed urgently.

Diarrhea and Dehydration

Diarrhea is a commonly reported adverse reaction. Severe or persistent diarrhea can cause dehydration and electrolyte disturbances.

Hand-Foot Skin Reaction

Patients may develop redness, tenderness, swelling, pain, or peeling of the skin on the palms and soles.

Impaired Wound Healing

Cabozantinib can interfere with wound healing. Patients should inform their healthcare team about planned operations, dental procedures, or other invasive interventions.

Osteonecrosis of the Jaw

Jaw-bone complications have been reported. Good oral hygiene and appropriate dental assessment are important during treatment.

Clinical Monitoring During Treatment

Monitoring helps healthcare professionals assess treatment response, identify adverse reactions, and determine whether treatment adjustments are necessary.

Depending on the patient’s circumstances, monitoring may include:

Monitoring areaClinical purpose
Blood pressureIdentify and manage hypertension
Kidney functionAssess renal health
Liver functionIdentify possible liver-related complications
Urine proteinMonitor proteinuria
Blood testsEvaluate general health and possible treatment effects
Gastrointestinal symptomsIdentify severe diarrhea or complications
Skin conditionAssess hand-foot skin reactions
Dental healthReduce and monitor jaw-related complications
General clinical conditionEvaluate treatment tolerance and disease status

The monitoring schedule should be determined by the treating oncology team.

Drug Interactions

Cabozantinib is affected by certain medicines that influence CYP3A4, an enzyme involved in drug metabolism.

Strong CYP3A4 inhibitors may increase cabozantinib exposure, while strong CYP3A4 inducers may reduce exposure.

Patients should inform their healthcare professional about all prescription medicines, over-the-counter products, vitamins, herbal preparations, and supplements they use.

No medication should be started, stopped, or changed without appropriate professional advice.

Special Patient Considerations

Before treatment, the healthcare professional may assess the patient’s:

  • Liver and kidney function.
  • Blood pressure and cardiovascular health.
  • History of bleeding or blood clots.
  • Gastrointestinal health.
  • Previous or planned surgery.
  • Dental condition.
  • Pregnancy status.
  • Current medicines and supplements.

Cabozantinib can cause fetal harm. Pregnancy prevention and breastfeeding considerations should be discussed with the treating healthcare professional.

Clinical Information Summary

Cabozantinib is a multi-target tyrosine kinase inhibitor that acts on proteins involved in tumor growth, cellular signaling, and angiogenesis.

Its established clinical applications include selected treatment settings for renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, neuroendocrine tumors, and medullary thyroid cancer, depending on the formulation and applicable approval.

Treatment requires appropriate patient selection, formulation-specific administration, clinical monitoring, and management of potential adverse reactions.

Important: Caboxen-specific manufacturer, dosage form, and regulatory indications must be confirmed from its actual product documentation. The clinical information for reference cabozantinib products should not automatically be treated as confirmed prescribing information for Caboxen.